• AT13387 Hsp90 Inhibitor Workflow for Cancer Research

  2026-09-01

  Build a mechanism-driven cancer biology workflow around AT13387, from Hsp90 client-protein loss to apoptosis and cell-release phenotyping. The approach also translates a recent norovirus–NINJ1 discovery into carefully bounded assay controls without confusing viral secretion biology with anticancer mechanism.

• GDC-0941: From PI3K Biology to Translational Strategy

  2026-09-01

  A mechanistic and strategic guide to using GDC-0941 to interrogate PI3K/Akt signaling, therapy resistance, cancer stem cell biology, and translational assay design.

• Triacetin: Workflows for Metabolic and GBM Research

  2026-08-31

  Triacetin, or glyceryl triacetate, supports distinct experimental workflows spanning glioblastoma cytotoxicity, adipogenesis research, and ocular formulation screening. This practical guide connects mechanism-aware assay design with concentration selection, controls, and troubleshooting for more reproducible results.

• Cy5 NHS ester(Et): Practical Labeling Guide

  2026-08-31

  Cy5 NHS ester(Et) is a water-soluble, amine-reactive fluorescent dye for covalent labeling of proteins, peptides, and other biomolecules. It is suited to aqueous or DMSO-based labeling workflows, but should not be used in ethanol-based protocols or for long-term storage of prepared solutions.

• NU7441 and DNA-PK: From Repair to Translation

  2026-08-30

  NU7441, also known as KU-57788, is more than a potent DNA-PK inhibitor: it is a mechanistic probe for connecting double-strand break repair, cell-cycle behavior, and emerging links between cytosolic DNA and TDP-43 homeostasis. This article outlines a translational framework for using NU7441 in DNA repair research, oncology research, and exploratory neurobiology while distinguishing evidence from hypothesis.

• Erlotinib: A Causal Map of EGFR–SCUBE3 Biology

  2026-08-29

  Erlotinib (NSC 718781) is more than an EGFR inhibitor: it is a practical perturbation tool for separating receptor-proximal signaling from SCUBE3-associated resistance and immune suppression. This article presents an assay framework that connects biochemical potency with translational cancer-model decisions.

• REV1–DHX36 Control of G4 DNA Replication

  2026-08-28

  The 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. Its two-tiered model clarifies how cells tolerate stabilized G4 structures and provides a mechanistic framework for studying replication stress and DNA damage response signaling.

• Olaparib Nanoparticles for Local Brain Tumor Delivery

  2026-08-28

  The reference study developed a sprayable pectin hydrogel containing PLA-PEG-coated etoposide and olaparib nanocrystals for local delivery after brain-tumor resection. Its findings support a preclinical formulation strategy that combines bioadhesion, sustained drug release, and nanoparticle distribution around a surgical cavity, while stopping short of demonstrating therapeutic efficacy in intracranial tumor models.

• NU7441 (KU-57788) DNA-PK Workflow Guide

  2026-08-27

  Turn DNA-PK inhibition into a controlled workflow for DNA repair research, oncology research, and cell-cycle analysis. This guide connects cancer-cell sensitization assays with a carefully bounded, hypothesis-generating approach to cytosolic-DNA and TDP-43 biology.

• iPSC Platform for Ultrarare Disease Trial Selection

  2026-08-26

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare ECHS1-related Leigh-like syndrome before clinical trial participation. The study shows how disease-relevant cellular models can connect molecular diagnosis, drug response, and longer-term clinical decision-making while also defining important limits for generalization.

• Linoleic Acid: From Membranes to Metabolic Signals

  2026-08-26

  Explore how Linoleic Acid (C18:2(9Z,12Z)) connects membrane behavior, redox biology, and selective translation. This article turns recent fasting research into a practical framework for choosing interpretable cell and erythrocyte assays.

• IR-1061 Near Infrared Fluorescent Dye Workflow

  2026-08-25

  IR-1061 supports OTN-NIR imaging workflows that prioritize deep-tissue contrast, but its hydrophobicity makes formulation design essential. This guide translates polymer-encapsulation findings into practical preparation, assay, optimization, and troubleshooting decisions for biomedical imaging researchers.

• Protease Inhibitor Cocktail EDTA-Free: K1010 Guide

  2026-08-25

  The Protease Inhibitor Cocktail is a 100X DMSO formulation for limiting endogenous proteolysis during protein extraction. Its EDTA-free design supports workflows that require divalent cations, including phosphorylation analysis and selected kinase assays.

• Olaparib and SmD2: Rethinking HCC PARP Assays

  2026-08-24

  Olaparib and AZD2281 provide a precise way to interrogate PARP-dependent DNA repair in hepatocellular carcinoma. This article explains how SmD2-regulated splicing can refine DNA damage response assays, biomarker interpretation, and combination-study design beyond conventional BRCA-based models.

• Sulfo-NHS-SS-Biotin: Cleavable Labeling Guide

  2026-08-24

  Sulfo-NHS-SS-Biotin provides water-compatible, amine-selective biotinylation for protein capture, detection, and reversible affinity workflows. It is suitable for intact-cell surface labeling and purified protein conjugation, but not for intracellular labeling or assays that require a permanently attached biotin tag.

8545 records 1/570 page Next 12345 下5页 Last page